Sulfatinib

DRUG4 trials

Sponsors

Hutchison Medipharma Limited, Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions

HealthyNeuroendocrine TumorsOsteosarcomaTumor

Phase 1

Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors

CompletedNCT02133157

Hutchison Medipharma LimitedTumor

Start: 2010-04-30End: 2014-10-31Updated: 2020-07-08

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

CompletedNCT02267967

Hutchison Medipharma LimitedNeuroendocrine Tumors

Start: 2014-10-31End: 2017-08-23Updated: 2018-11-13

A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)

CompletedNCT02320409

Hutchison Medipharma LimitedHealthy

Start: 2014-12-31End: 2015-04-30Updated: 2020-05-08

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Not yet recruitingNCT05590572

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityOsteosarcoma

Start: 2023-01-31End: 2027-12-31Target: 148Updated: 2022-10-21

Related Papers

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors

Investigational New Drugs2023-04-198 citations

Abstract CT115: Efficacy of surufatinib in Western patients with pancreatic neuroendocrine tumors

Cancer Research2020-08-15

Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects.

2020-08-134 citations

Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study

Oncotarget2017-02-0156 citations